Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.33 |
| ▸ | TPH1 | P17752 | 3/20 | 0.32 |
| ▸ | TPH2 | Q8IWU9 | 3/20 | 0.32 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 4/20 | 0.31 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16426550 | 0.84 | PTGS1 (0.42) | TPH1TPH2WDR91RAB9ANPC1 | |
| SCHEMBL17863729 | 0.80 | CYP19A1 (0.45) | TPH1TPH2WDR91RAB9ANPC1 | |
| SCHEMBL17863736 | 0.76 | LMNA (0.33) | — | |
| SCHEMBL17863730 | 0.76 | PKM (0.33) | PKM | |
| SCHEMBL17863728 | 0.76 | CCNE1 (0.31) | — | |
| SCHEMBL18658780 | 0.75 | WDR91 (0.38) | TPH1TPH2WDR91RAB9ANPC1 | |
| SCHEMBL17863720 | 0.75 | DAO (0.32) | — | |
| SCHEMBL1665689 | 0.72 | TPH1 (0.31) | TPH1TPH2MAPTSMN1; SMN2 | |
| SCHEMBL19291869 | 0.69 | TPH1 (0.31) | TPH1TPH2SMN1; SMN2 | |
| SCHEMBL17454368 | 0.69 | TP53 (0.49) | RAB9ANPC1MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512144-B2 | Imidazothiazole sufonamides as nematicides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20160176898-A1 | IMIDAZOTHIAZOLE SUFONAMIDES AS NEMATICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176898-A1 | IMIDAZOTHIAZOLE SUFONAMIDES AS NEMATICIDES | NISCH, TST, SULT1E1 | KDM1A 3330/4885TPH1 2350/4885TPH2 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.